This Issue, we’re taking a deep dive into a number of policy, business and commercial stories that are relevant—in various degrees— to psychedelics. We broadly break up our coverage into two buckets: Policy and Related and Business and Commercial, with around a half-dozen stories in each.This Issue is free. Our independent coverage of psychedelic business, policy and research is made possible by…
